 IRVINE, CA ACCESSWIRE April 27, 2020 Hancock Jaffe Laboratories, Inc. HJLIHJLIW, a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 1 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be 0.53, which is priced at-the-market under Nasdaq rules. Under the terms of the purchase agreement, HJLI has agreed to sell 1,886,800 shares of its common stock. 